Related Experiment Videos
Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with
1The First Department of Internal Medicine, Kansai Medical University, Osaka, Moriguchi, Japan. fwkg4681@mb.infoweb.ne.jp
Abstract:
We investigated the significance of platelet activation and platelet-derived microparticles (PMP) in 14 patients with systemic inflammatory response syndrome (SIRS) and hematological malignancies. In the phenotypic analysis of lymphocytes, there was a significant decrease of total and activated T cells after panipenem/betamipron (PAPM/BP) treatment (p<0.05). The percentages of helper/inducer T cells and suppressor/cytotoxic T cells were insignificantly decreased after PAPM/BP treatment. The number of natural killer (NK) cells of potent activity was significantly decreased after treatment (p<0.05). The levels of the cytokines interleukin (IL)-1beta, IL-6, and IL-8 in the patients were increased before treatment. IL-1beta concentrations were not changed after treatment. In contrast, the IL-6 and IL-8 levels were significantly decreased (p<0.05) after treatment, while tumor necrosis factor (TNF)-alpha and interferon gamma remained almost normal. We found an increase of soluble IL-2 receptor (sIL-2R) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels in the patients before treatment. After treatment, the sIL-2R concentrations tended to be decreased and sVCAM-1 levels showed a significant decrease (p<0.01). In contrast, soluble thrombomodulin (sTM) level did not change. Regarding the platelet activation markers, CD62P, CD63, and PMP levels in the patients were increased before treatment. CD62P and CD63 tended to be decreased after treatment, whereas PMP levels were significantly reduced from 1,056+/-103 to 762+/-64/10(4) platelets (p<0.05). Furthermore, CD62P, CD63, and PMP correlated with the levels of IL-6 and IL-8. These results suggest that activated platelets and PMP may be predictive markers in pre-disseminated intravascular coagulation and hypercytokine conditions related to SIRS.
Insights
Activated platelets and platelet-derived microparticles (PMP) may predict pre-disseminated intravascular coagulation in patients with systemic inflammatory response syndrome (SIRS). Treatment with panipenem/betamipron (PAPM/BP) reduced PMP levels and inflammatory cytokines.
Area of Science:
- Hematology
- Immunology
- Critical Care Medicine
Background:
- Systemic inflammatory response syndrome (SIRS) involves complex immune dysregulation.
- Platelet activation and platelet-derived microparticles (PMP) are implicated in inflammatory conditions.
- Hematological malignancies can exacerbate SIRS and associated complications.
Purpose of the Study:
- To investigate the role of platelet activation and PMP in SIRS patients with hematological malignancies.
- To assess the impact of panipenem/betamipron (PAPM/BP) treatment on immune markers and platelet activation.
Main Methods:
- Phenotypic analysis of lymphocyte subsets (T cells, NK cells).
- Measurement of serum cytokine levels (IL-1beta, IL-6, IL-8, TNF-alpha, IFN-gamma).
- Quantification of soluble receptors (sIL-2R, sVCAM-1, sTM) and platelet activation markers (CD62P, CD63, PMP).
Main Results:
- PAPM/BP treatment significantly decreased total and activated T cells, and NK cells.
- IL-6 and IL-8 levels were significantly reduced post-treatment, while IL-1beta remained unchanged.
- Platelet activation markers (CD62P, CD63) and PMP levels significantly decreased after PAPM/BP treatment and correlated with IL-6 and IL-8.
Conclusions:
- Activated platelets and PMP may serve as predictive markers for pre-disseminated intravascular coagulation in SIRS.
- PAPM/BP treatment effectively modulates inflammatory cytokine profiles and reduces platelet activation markers.
- These findings highlight the potential of targeting platelet activation in managing SIRS-related complications.